Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) General Counsel Sells $125,750.00 in Stock

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) General Counsel Kurt Oreshack sold 25,000 shares of the stock in a transaction on Friday, January 31st. The shares were sold at an average price of $5.03, for a total transaction of $125,750.00. Following the completion of the transaction, the general counsel now directly owns 167,618 shares in the company, valued at $843,118.54. This trade represents a 12.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Maravai LifeSciences Trading Down 2.4 %

Shares of MRVI stock opened at $4.93 on Monday. Maravai LifeSciences Holdings, Inc. has a 1-year low of $4.28 and a 1-year high of $11.56. The firm’s 50-day simple moving average is $5.42 and its 200-day simple moving average is $7.13. The firm has a market cap of $1.24 billion, a P/E ratio of -3.01 and a beta of -0.07. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94.

Maravai LifeSciences (NASDAQ:MRVI) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.09) earnings per share for the quarter. The company had revenue of $65.20 million during the quarter, compared to analyst estimates of $67.58 million. Maravai LifeSciences had a negative net margin of 81.13% and a negative return on equity of 6.61%. During the same quarter last year, the business earned ($0.02) EPS. As a group, equities analysts forecast that Maravai LifeSciences Holdings, Inc. will post -0.24 EPS for the current year.

Institutional Investors Weigh In On Maravai LifeSciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in MRVI. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Maravai LifeSciences in the 2nd quarter valued at about $32,000. Venturi Wealth Management LLC acquired a new position in Maravai LifeSciences during the third quarter valued at approximately $47,000. FNY Investment Advisers LLC grew its stake in Maravai LifeSciences by 600.0% during the fourth quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company’s stock worth $38,000 after buying an additional 6,000 shares during the period. Custom Index Systems LLC purchased a new stake in Maravai LifeSciences during the third quarter worth approximately $97,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Maravai LifeSciences in the third quarter worth $105,000. 50.25% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

MRVI has been the topic of several research reports. The Goldman Sachs Group downgraded shares of Maravai LifeSciences from a “neutral” rating to a “sell” rating and lowered their price objective for the stock from $7.00 to $4.25 in a research report on Thursday, December 5th. Guggenheim assumed coverage on shares of Maravai LifeSciences in a report on Thursday, December 19th. They issued a “neutral” rating for the company. Robert W. Baird reduced their price objective on Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating for the company in a report on Friday, November 8th. Wolfe Research started coverage on shares of Maravai LifeSciences in a research report on Thursday, November 14th. They set a “peer perform” rating for the company. Finally, Royal Bank of Canada reduced their price objective on Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Maravai LifeSciences has a consensus rating of “Hold” and an average price target of $10.28.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.